Skip to main content

Advertisement

Table 3 Patient characteristics

From: Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events

  Total
(N = 17)
Age, years
 Mean (SD) 68.8 (8.5)
 Median 68
 Min-max 54–84
Sex
 Male 15 (88.2%)
 Female 2 (11.8%)
Race
 White 13 (76.4%)
 Black or African American 2 (11.8%)
 Asian 0
 Native Hawaiian or other Pacific Islander 0
 American Indian or Alaskan native 0
 Other 1 (5.9%)
 Not reported 1 (5.9%)
Ethnicity
 Hispanic or Latino 2 (11.8%)
 Not Hispanic or Latino 13 (76.4%)
 Not reported 2 (11.8%)
Living situation
 Living alone 6 (35.3%)
 Living with partner or spouse, family, or friends 9 (52.9%)
 Other 1 (5.9%)
 Not reported 1 (5.9%)
Employment status
 Employed full time 1 (5.9%)
 Employed part time 0
 Unemployed 1 (5.9%)
 Retired 10 (58.8%)
 Disabled 2 (11.8%)
 Other 2 (11.8%)
 Not reported 1 (5.9%)
Education levela
 Secondary/high school 2 (11.8%)
 Some college 7 (41.2%)
 College degree 4 (23.5%)
 Postgraduate degree 2 (11.8%)
 Other or Missing 2 (11.8%)
General health (past week)
 Very good 3 (17.7%)
 Good 6 (35.3%)
 Fair 5 (29.4%)
 Poor 2 (11.8%)
 Very poor 0
 Not reported 1 (5.9)
Child-Pugh class
 A—with no locoregional treatment 3 (17.7%)
 A—with locoregional treatment but before sorafenib treatment 4 (23.5%)
 A—after sorafenib treatment 3 (17.7%)
 B—with any treatment experience 7 (41.2%)
ECOG performance status
 0 8 (47.1%)
 1 9 (52.9%)
Comorbiditiesa
 Asthma 2 (11.8%)
 Anxiety/depression 5 (29.4%)
 Arthritis 3 (17.7%)
 COPD (emphysema, chronic bronchitis) 3 (17.7%)
 Diabetes 4 (23.5%)
 Hypertension (high blood pressure) 10 (58.8%)
 Chest pain/abdominal pain 1 (5.9%)
 No other health conditions 2 (11.8%)
HCC treatments receiveda
 Chemotherapy 2 (11.8%)
 Transarterial chemoembolization 5 (29.4%)
 External radiation 1 (5.9%)
 Ablation 8 (47.1%)
 Liver resection 4 (23.5%)
 Y90 radioembolization 6 (35.3%)
 Sorafenib 5 (29.4%)
Current medicationsa
 Antibiotics 2 (11.8%)
 Nutritional support 2 (11.8%)
 Pain medications/corticosteroids/anti-inflammatory agents 5 (29.4%)
 Drugs for gastrointestinal-related disorders 6 (35.3%)
 Drugs for anemia 1 (5.9%)
 None 2 (11.8%)
  1. COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma
  2. aNot mutually exclusive